HMG-CoA reductase inhibitors: Is the endothelium the main target?

Cardiology

Volumn 95, Issue 1, 2001, Pages 9-13

  Puddu, Paolo ^a   Puddu, Giovanni M ^a   Muscari, Antonio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Atherosclerosis; Endothelium derived factors; Statins

Indexed keywords

ENDOTHELIN 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; HUMAN; HYPERCHOLESTEROLEMIA; PRIORITY JOURNAL; REVIEW; THROMBOSIS; VASCULAR ENDOTHELIUM;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NITRIC OXIDE;

EID: 0034991707     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000047336     Document Type: Review

References (64)

1. The evolving role of statins in the management of atherosclerosis
2. Current perspectives on statins
3. Statins do more than just lower cholesterol
4. Cholesterol lowering: Should it continue to be the last thing we do?
5. Statins and coronary artery disease: It's the clinical endpoints that count
6. Cholesterol lowering and endothelial function
7. Low-density lipoprotein-independent effects of statins
8. Statins: Possibly more than just lowering of the lipid level
9. Atherosclerosis - An inflammatory disease
10. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication
11. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus
12. Impaired endothelium-dependent vasodilation in patients with essential hypertension: Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway
13. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia: Role of oxidized LDL
14. Homocysteine and risk for athero-thrombotic events
15. Endothelial dysfunction in hypertension
16. Oxidized lipoproteins and nitric oxide
17. Hypercholesterolemia increases endothelial superoxide anion production
18. Atherosclerosis and the two faces of endothelial nitric oxide synthase
19. HMG-CoA reductase inhibition inhibits vascular NADH oxidase activity, prevents uncoupling of nitric oxide synthase and improves endothelial dysfunction in cholesterol fed rabbits
20. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys
21. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions
22. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
23. HMG CoA reductase inhibtion promotes NO production by decreasing abundance and the inhibitory interaction of caveolin with the endothelial nitric oxide synthase
24. Statin therapy counteracts the deleterious effects of increased oxidative stress on atherosclerotic disease progression
25. A novel potent vaosconstrictor peptide produced by vascular endothelial cells
26. Reciprocal regulation of endothelin-1 and endothelial constitutive NOS in proliferating endothelial cells
27. Lipopolysaccharide and interleukin 1 augment the effects of hypoxia and inflammation in human pulmonary arterial tissue
28. Effects of interferon-γ on nitric oxide synthase activity and endothelin-1 production by vascular endothelial cells
29. Enhanced endothelin-mediated coronary vasoconstriction and attenuated basal nitric oxide activity in experimental hypercholesterolemia
30. Impaired vasodilation of forearm vessels in hypercholesterolemic humans
31. Modulation of vasomotor tone in humans: Progressive endothelial dysfunction with different early stages of atherosclerosis
32. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells
33. HMG CoA reductase inhibition attenuates vascular endothelin-1 generation in experimental atherosclerosis
34. Plasma endothelin-1 levels in stable and unstable angina
35. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) Trial
36. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia
37. Induction of interleukin-1 production by ligands binding to the scavenger receptor in human monocytes and the THP-1 cell line
38. Effect of dietary antioxidant combinations in humans: Protection of LDL by vitamin E but not by betacarotene
39. Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: In vitro and ex vivo studies
40. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: In vitro and in vivo studies
41. Effective lovastatin therapy in elderly hypercholesterolemic patients - An antioxidative impact?
42. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: A double-blind, placebo-controlled study
43. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin
44. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages
45. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle
46. Direct antioxidant effects of atorvastatin and an active metabolite: A comparative analysis
47. Simvastatin inhibits leukocyte-endothelium interaction in vivo under normocholesterolemic conditions: Essential role of endothelial nitric oxide synthase
48. Direct vascular effects of HMG-CoA reductase inhibitors
49. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats
50. Pravastatin reduces soluble markers of inflammation and improves peripheral endothelial function in heart transplant recipients
51. Short-term atorvastatin therapy reduces monocyte-related inflammatory markers in the serum of hypercholesterolaemic patients
52. Cerivastatin inhibits metalloproteinase production by human vascular smooth muscle cells in response to inflammatory stimuli, a possible mechanism for plaque stabilisation
53. The serum immunoglobulin IgE, interleukin-4 and soluble form receptor CD23 dynamic changes in patients with hypercholesterolaemia II B treated with pravastatin
54. Lipid lowering improves endothelial functions
55. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease
56. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions
57. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
58. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
59. Cholesterol reduction improves myocardial perfusion abnormalities in normolipidemic patients with coronary artery disease (CAD)
60. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease
61. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion
62. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomogaphy after dipyridamole in patients with coronary artery disease: A potential noninvasive marker of healing coronary endothelium
63. Impaired endothelium-dependent vasodilation in the forearm of patients with endogenous hypertriglyceridemia: Reversal upon lipid-lowering therapy by atorvastatin
64. Long-term effects of pravastatin on plasma concentration of C-reactive protein